Abstract:Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin's surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, 8a exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved in vivo antitumor effects. The X-ray crystal structure suggested that 8a both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01961?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961</a>.Characterization of key compounds, antiproliferation activity data, MTD, table of protein crystal data collection and refinement statistics, and HPLC purity traces for key final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">CSV</a>)Structural data for compounds 6a, 6d, and 6r (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">PDB</a>)This article has not yet been cited by other publications.

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective

Structural perspective on the design of selective DYRK1B inhibitors

Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs

Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

Identification, Structure Modification, and Characterization of Potential Small-Molecule SGK3 Inhibitors with Novel Scaffolds

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

Exploring the Selectivity of Tetrahydropyrido[1,2-a]isoindolone Derivatives to GSK3 beta and CDK5 by Computational Methods

Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations

Studies of glycogen synthase kinase-3 inhibitors

Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate

Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta

Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure

In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation

Glycogen synthase kinase-3β inhibitors as a novel promising target in the treatment of cancer: Medicinal Chemistry Perspective

Identification of Novel Inhibitors Targeting SGK1 via Ensemble-Based Virtual Screening Method, Biological Evaluation and Molecular Dynamics Simulation

Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases

The Nitro Group Reshapes the Effects of Pyrido[3,4-g]quinazoline Derivatives on DYRK/CLK Activity and RNA Splicing in Glioblastoma Cells

Discovery of Novel and Selective SIK2 Inhibitors by the Application of AlphaFold Structures and Generative Models.